Pradimicins A, B and C1"4* and benanomicins A and B5 6) are produced by Actinomadura hibisca P157-2 (ATCC53557) and an actinomycete numbered MH193-16F4, respectively. They belong to a novel group of antifungal antibiotics possessing a core structure of glycosylated dihydrobenzo [a] naphthacenequinone substituted with D-alanine at C-15 (Fig. 1) . Pradimicins D and E (glycine analogs of pradimicins A and C) which have also been isolated from fermentations of A. hibisca PI57-2 and its mutant strains, showed antifungal activity similar to pradimicin A7). Biosynthetically, the aglycone of pradimicin A is derived from acetate and alanine, as shown by feeding studies with 13C-enriched precursors8). Efficient incorporation of both d-and L-alanines into the D-alanine side chain of pradimicin A suggested that D-alanine might act as the direct precursor for the side chain. Recently, through the addition of D-serine to antibiotic fermentations, the formation of new active metabolites, pradimicins FA-1 and FA-2, has been accomplished9*. Pradimicins FA-1 and FA-2 (D-serine analogs of pradimicins A and C) showed antifungal activity similar to pradimicin A. Although pradimicins A, B, C, D, E, FA-1 and FA-2 exhibited significant in vivo activity against Candida albicans A9540systemic infections in mice4'7>9), their limited solubility in aqueous media posed some problems in further development. In order to obtain water-soluble analogs that retain the antifungal activity of pradimicin A, a program of chemical modification was undertaken, using the fermentation products as starting materials. Weanticipated that incorporation of a second methyl group at the basic nitrogen atom in the sugar moiety would change the physico-chemical properties of the parent molecule without impairing the antifungal activity. This report describes the synthesis and evaluation of TV,TV-dimethyl pradimicins (1, 2 and 3).
Chemistry
The reductive alkylation of pradimicins A, E, and FA-2 with formaldehyde yielded N,Ndimethylpradimicin C (1), TV,iV-dimethylpradimicin E (2) and 7V,7V-dimethylpradimicin FA-2 (3), respectively. The progress of the reaction was monitored by HPLCon a YMC A-301-3 ODScolumn using an acetonitrile concentration gradient in 0.15% phosphate buffer (pH 3.5) from 15% to 55%. The N-H2 pradimicins eluted first, then the TV-methyl pradimicins, and finally the TV,TV-dimethyl derivatives. The products were purified by Diaion HP-20 column chromatography and isolated in an analytically pure zwitterionic form.
The structures of TV,TV-dimethyl pradimicins (1, 2 and 3) were confirmed by FAB-MS,combustion analysis and *H NMRspectroscopy.
In Vitro Antifungal Evaluation Table 1 summarizes the MICs determined by the agar dilution method on Sabouraud dextrose agar medium for 1, 2, 3, pradimicin A (PRD-A), amphotericin B (AMP-B) and ketoconazole (KCZ) against a panel of 12 yeasts and 7 filamentous fungi. TV,TV-Dimethyl pradimicins (1, 2 and 3) showed significant improvement in activity against yeasts. The MICs against 3 isolates of C albicans ranged from 3.1-12.5fig/ml for 1, 2, and 3 as compared to MICs of 12.5-50^^1 for PRD-A. TV,TV-Dimethyl pradimicins (1, 2 and 3) also have better activity against isolates of Candida tropicalis, Candida parapsilosis and Candida krusei than PRD-A,demonstrating an expansion of the PRD-Aspectrum. The MICagainst AMP-B-resistant C. albicans (ATCC 38247) ranged from 0.8 -3.1 jug/ml for 1, 2, 3 and PRD-A, indicating that there is no cross resistant between pradimicins and AMP-B.TV,TV-Dimethyl pradimicins (1 and 3) retained the pradimicin activity against filamentous fungi, while the activity of 2 was significantly reduced against them whencompared to PRD-A.
Water Solubility and Animal Tolerance Table 2 lists data for the solubility in phosphate buffered saline containing Ca2+ and Mg2+and animal tolerance of TV,TV-dimethyl pradimicins (1, 2 and 3) and PRD-A. No acute toxicity, as measured by mortality, was observed with the water-soluble derivatives (2 and 3) at doses up to 600mg/kg in mice after an intravenous administration.
Ataxia was observed with 2 at a dose of 600mg/kg, while MICsdetermined by the agar dilution method on Sabouraud dextrose agar medium, pH7.0; inoculum size: 106 cells/ml (5 /il/spot). A^N-dimethylpradimicin FA-2 (3) appeared to be well tolerated; no apparent side effects following injections of 3 up to 600mg/kg were noted. In Vivo Antifungal Evaluation The in vivo activity of A^AT-dimethylpradimicins E (2) and FA-2 (3) against experimental systemic infections with C. albicans, Cryptococcus neoformans and Aspergillus fumigatus is shown in Table 3 . Both 2 and 3 showed excellent activity against C. albicans and somewhatreduced activity against A. fumigatus, when compared to PRD-Aby a single intravenous administration in normal mice.
Discussion
The results of the present study have provided a novel series of A^TV-dimethyl pradimicin derivatives which have excellent activity against C. albicans as well as other pathogenic fungi. The data presented in Table 2 suggest a positive correlation between the water solubility and acute toxicity; the water-soluble derivatives (2) and (3) showed superior tolerance in mice. The results thus appear to indicate that incorporation of a second methyl group at the basic nitrogen atom in the sugar moiety improved the properties of the glycine and serine analogs of PRD-Ain aqueous media. N,7V-Dimethylpradimicin C (1) was more toxic than PRD-A. 7V,JV-Dimethylpradimicin FA-2 (3) has been selected for development as a therapeutic agent for systemic fungal infections based on its spectrum of in vitro activity, solubility, in vivo activity and tolerance in mice. Further evaluation of 3 is in progress.
Experimental General Methods
All mp's were determined with a Yanaco micro melting point apparatus and are uncorrected. UV and IR spectra were recorded on a Jasco UVIDEC-610C spectrometer and a Jasco IR-810 spectrometer, respectively. *H NMR spectra were recorded on a Jeol JNM-GX400 spectrometer. Mass spectra were obtained with a Jeol JMS-AX505Hspectrometer. AMP-B(Fungizone, sodium deoxycholate complex) was obtained from Nippon Squibb Co. KCZwas obtained from Janssen Pharmaceuticals.
Reductive Methylation of Pradimicins
The following procedure is an example for preparation of iV,iV-dimethyl pradimicins. A solution of pradimicin E hydrochloride (485mg) in water (40ml) was adjusted to pH 8.0 with 1 n NaOH at 25°C, diluted with acetonitrile (40ml), and HCHO (37%, 1.6ml) and NaBH3CN (240mg) were sequentially added. The mixture was stirred for 15 hours and the solvent was removed in vacuo. The residue was dissolved in water (50ml), adjusted to pH 1 1.0, and added dropwise to acetone (300ml) while stirring. The resulting precipitate was collected by centrifugation and redissolved in water. The solution was adjusted to pH 2.0 with 6n HC1 and chromatographed on a column of Diaion HP-20 eluted with 3 :2, acetone-water (pH 3.0). The orange eluate was concentrated in vacuo to 5ml and adjusted to pH 5.5. The resulting solid was collected, washed successively with water and acetone, and dried at 60°C under vacuum for 40 hours to afford 364mg (73% yield) of A^-dimethylpradimicin E (2): MP 214~218°C (dec); UV (0.01 n NaOH) Amaxnm (e) 233.6 (32,900), 319. 
Determination of Water Solubility
The water solubility of each compound was assessed in Dulbecco's phosphate buffered saline containing 0.9mM of CaCl2 and 0.5him of MgCl2, pH 7.2. Each sample (1~20mg/ml) was sonicated at 30°C for 10 minutes and allowed to stand at 25°C for 2 hours. The supernatant was collected by centrifugation at 12,000 rpm for 10 minutes, diluted 50-fold with 0.01 n NaOH, and the absorption value at 500 nmwas read. On the basis of the absorption value, the solubility of the compound was calculated.
Test Strains A panel of 12 yeasts and 7 filamentous fungi was used for comparative studies. Yeasts were cultured at 28°C in YGP medium (yeast extract (0.2%), glucose (1.5%), peptone (0.5%), K2HPO4 (0.05%), MgSO4 (0.05%)). The inocula for the susceptibility test were broth dilutions or suspensions of mid-exponentially growing cells. Fungi were cultured at 28°C on YGPagar medium for 14 days and a suspension of spores in 0.2% Tween 80 was filtered through a gauze.
Antifungal Spectrum of Activity The susceptibility of yeasts and filamentous fungi was determined by the agar dilution method on Sabouraud dextrose agar medium (pH 7.0). Test compounds and AMP-Bwere dissolved in 10% DMSO at a concentration of 1,000/jg/ml; 2-fold serial dilutions thereof were made in water to give final concentrations ranging from 0.05 to 100/zg/ml. KCZwas dissolved in 10% DMSOcontaining a trace of 1 n HC1at a concentration of 1,000jug/ml and diluted with water for use at concentrations ranging from 0.05 to 100^g/ml. One part of each solution was mixed with nine parts of molten agar mediumin Petri dishes. A final inoculum of 106 cells/ml (0.005 ml of cell suspension/spot) was used. All the organisms were incubated at 28°C for 40 hours. The MICin each case was defined as the lowest concentration of antibiotic showing no distinct growth or less than five discrete colonies/spot.
Acute Toxicity Compounds were dissolved in 10% DMSO and administered once intravenously to groups of 5 male ICR mice at the dosed volume of 0.1 ml per 10g body weight. The animals were observed daily for 10 days for physical and behavioral signs of toxicity.
In Vivo Antifungal Activity The in vivo activity against systemic infections with C. albicans A9540(106 cells/mouse), C. neoformans IAM4514 (106cells/mouse) and A. fumigatus IAM2034 (107 cells/mouse) was examined in normal mice. Male ICR mice weighing 20~24g were infected intravenously. Groups of five mice at each dose level were treated with the test compounds in 10% DMSO.The 50% protection dose (PD50) was calculated by the method of Litchfield and Wilcoxon10) from the survival rate 20 days after the fungal challenge. Untreated animals died 7 to 15 days post infection.
